Updated APHINITY Supports Benefit of Anti-HER2 Combo

]]>(MedPage Today) -- Adding a second anti-HER2 agent to trastuzumab (Herceptin) plus chemotherapy in the adjuvant setting continued to show promise for select women with early HER2-positive breast cancer, according to a six-year analysis from the...